Cochrane · systematic review · CD003898
Inhaled magnesium sulfate in the treatment of acute asthma
Knightly, R, Milan, SJ, Hughes, R, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
17
current version
GRADE rated
16
No studies
1
Included studies
NR
No studies 1 · 5.9%Ungraded 0 · 0%Very low 3 · 17.6%Low 9 · 52.9%Moderate 3 · 17.6%High 1 · 5.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyMgSO4 + SABA + ipratropium compared to SABA + ipratropium in the treatment of acute asthma
Population: adults and children with acute exacerbation of asthma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pulmonary function (% predicted FEV1) (90 to 120 minutes) MgSO4 + SABA + ipratropium vs SABA + ipratropium | no estimate extracted | 2 studies · 120 participants | Very low Downgraded: risk of bias, imprecision |
Pulmonary function % predicted PEF (60 minutes) MgSO4 + SABA + ipratropium vs SABA + ipratropium | no estimate extracted | 2 studies · 636 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Clinical severity scores (60 minutes) MgSO4 + SABA + ipratropium vs SABA + ipratropium | no estimate extracted | 2 studies · 1130 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Admission at first presentation MgSO4 + SABA + ipratropium vs SABA + ipratropium | RR 0.95 [0.91, 1] | 4 studies · 1308 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Readmission (7 to 30 days) MgSO4 + SABA + ipratropium vs SABA + ipratropium | RR 1.8 [0.84, 3.87] | 2 studies · 750 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Serious adverse events (during admission) MgSO4 + SABA + ipratropium vs SABA + ipratropium | no estimate extracted | 2 studies · 557 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Any adverse event (during admission) MgSO4 + SABA + ipratropium vs SABA + ipratropium | no estimate extracted | 2 studies · 1197 participants | High |
MgSO4 + SABA compared to SABA in the treatment of acute asthma
Population: adults and children with acute exacerbation of asthma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pulmonary function % predicted FEV1 (20 minutes to 2 to 3 h) MgSO4 + SABA vs SABA | no estimate extracted | 4 studies · 208 participants | Low Downgraded: risk of bias, imprecision |
Pulmonary function PEF L/min ‐ Adults (20 minutes to 2 to 3 h) MgSO4 + SABA vs SABA | no estimate extracted | 3 studies · 155 participants | Low Downgraded: risk of bias, imprecision |
Pulmonary function PEF L/min ‐ Children (60 minutes) MgSO4 + SABA vs SABA | no estimate extracted | 1 study · 80 participants | Low Downgraded: risk of bias, imprecision |
Admission to hospital at initial presentation MgSO4 + SABA vs SABA | RR 0.78 [0.52, 1.15] | 6 studies · 375 participants | Low Downgraded: risk of bias, imprecision |
Serious adverse events (During ED/hospital admission) MgSO4 + SABA vs SABA | no estimate extracted | 5 studies · 243 participants | Low Downgraded: risk of bias, imprecision |
Any adverse events (During ED/hospital admission) MgSO4 + SABA vs SABA | no estimate extracted | 5 studies · 694 participants | Low Downgraded: risk of bias, imprecision |
MgSO4 compared to SABA in the treatment of acute asthma
Population: adults and children with acute exacerbation of asthma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Lung function MgSO4 vs SABA | no estimate extracted | NR | No studies |
Clinical severity score ‐ Fischl index (120 minutes) MgSO4 vs SABA | no estimate extracted | 3 studies · 93 participants | Very low Downgraded: risk of bias, imprecision |
Admission to hospital at initial presentation MgSO4 vs SABA | RR 0.53 [0.05, 5.31] | 1 study · 33 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Serious adverse events (During ED/hospital admission) MgSO4 vs SABA | no estimate extracted | 2 studies · 53 participants | Low Downgraded: risk of bias, imprecision |
MgSO4 + B2‐agonists compared to B2‐agonists alone for acute asthma
Population: people with acute asthma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pulmonary Function testing FEV1 MgSO4 + B2‐agonists vs B2‐agonists alone | SMD 0.23 | 3 studies · 188 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Pulmonary function testing PEF ‐ up to 60 minutes MgSO4 + B2‐agonists vs B2‐agonists alone | MD 7.07 | 2 studies · 135 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Pulmonary function testing PEF ‐ Discharge MgSO4 + B2‐agonists vs B2‐agonists alone | MD 0.68 | 1 study · 26 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Admission to Hospital MgSO4 + B2‐agonists vs B2‐agonists alone | RR 0.76 [0.49, 1.16] | 4 studies · 249 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Serious Adverse Events MgSO4 + B2‐agonists vs B2‐agonists alone | RD 0 | 4 studies · 223 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Mild‐Moderate Adverse Events MgSO4 + B2‐agonists vs B2‐agonists alone | no estimate extracted | 3 studies · 209 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
MgSO4 compared to B2‐agonist for people with acute asthma
Population: patients with people with acute asthma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pulmonary Function testing PEF MgSO4 vs B2‐agonist | no estimate extracted | 3 studies · 113 participants | Moderate Downgraded: risk of bias, inconsistency |
Admision to hospital MgSO4 vs B2‐agonist | RR 0.53 | 1 study · 33 participants | Low Downgraded: risk of bias, inconsistency |
Serious Side Effects MgSO4 vs B2‐agonist | RD 0 | 1 study · 33 participants | Low Downgraded: risk of bias, inconsistency |
Mild‐Moderate Side Effects MgSO4 vs B2‐agonist | no estimate extracted | 1 study · 33 participants | Low Downgraded: risk of bias, inconsistency |